Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.

Annikka Weissferdt,Apar Pataer,Ara A Vaporciyan,Arlene M Correa,Boris Sepesi,Cesar A Moran,Ignacio I Wistuba,Jack A Roth,Jitesh Baban Shewale,John V Heymach,Neda Kalhor,Tina Cascone,Wayne L Hofstetter,J Jack Lee,Stephen G Swisher

Clinical Lung Cancer（2020）

引用 73|浏览135

暂无评分

摘要

MPR is significantly predictive of long-term OS in neoadjuvant chemotherapy-treated patients with NSCLC. MPR may serve as a surrogate endpoint for evaluating novel chemotherapies and immunotherapy response in biomarker-driven translational clinical trials.

查看译文

关键词

Endpoint,Lung cancer,MPR,Neoadjuvant chemotherapy,OS

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要